David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center in Boston, Massachusetts presented results from the KEYNOTE-427 study at the Genitourinary Cancers Symposium (GUCS) 2019. As most renal cell carcinomas are clear cell in origin, study data directing treatment for other histologies are limited, and patients with non-clear cell renal cell carcinoma (nccRCC) are often excluded from clinical trials. KEYNOTE-427, one of the first trials inclusive of patients with nccRCC, has shown promising activity with monotherapy using pembrolizumab.

Learn more by clicking here.